Last reviewed · How we verify
ABC/DTG/3TC immediate release tablets
A fixed-dose combination of three antiretroviral agents that inhibit HIV reverse transcriptase and integrase to suppress viral replication.
A fixed-dose combination of three antiretroviral agents that inhibit HIV reverse transcriptase and integrase to suppress viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in adolescents and children (age and weight-dependent formulations).
At a glance
| Generic name | ABC/DTG/3TC immediate release tablets |
|---|---|
| Sponsor | ViiV Healthcare |
| Drug class | Antiretroviral combination (NRTI + INSTI) |
| Target | HIV reverse transcriptase, HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Abacavir (ABC) and lamivudine (3TC) are nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase, while dolutegravir (DTG) is an integrase strand transfer inhibitor (INSTI) that prevents viral DNA integration into the host genome. Together, they provide complementary mechanisms to suppress HIV replication and reduce viral load.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
- HIV-1 infection in adolescents and children (age and weight-dependent formulations)
Common side effects
- Hypersensitivity reaction (abacavir)
- Nausea
- Diarrhea
- Headache
- Insomnia
- Fatigue
Key clinical trials
- Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019 (PHASE3)
- The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age (PHASE1, PHASE2)
- Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABC/DTG/3TC immediate release tablets CI brief — competitive landscape report
- ABC/DTG/3TC immediate release tablets updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI